Activity and the metabolic activation pathway of the potent and selective hepatitis C virus pronucleotide inhibitor PSI-353661

Antiviral Research

Volumn 91, Issue 2, 2011, Pages 120-132

  Furman, Phillip A ^a   Murakami, Eisuke ^a   Niu, Congrong ^a   Lam, Angela M ^a   Espiritu, Christine ^a   Bansal, Shalini ^a   Bao, Haiying ^a   Tolstykh, Tatiana ^a   Micolochick Steuer, Holly ^a   Keilman, Meg ^a   Zennou, Veronique ^a   Bourne, Nigel ^b   Veselenak, Ronald L ^b   Chang, Wonsuk ^a   Ross, Bruce S ^a   Du, Jinfa ^a   Otto, Michael J ^a   Sofia, Michael J ^a  

^a PHARMASSET INC   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

2 Deoxy 2 fluoro 2 C methylguanosine 5 monophosphate; Antiviral; Hepatitis C virus; Nucleotide analog; Phosphoramidate; Prodrug

Indexed keywords

2 [[5 (2 AMINO 6 METHOXYPURIN 9 YL) 4 FLUORO 3 HYDROXY 4 METHYLTETRAHYDROFURAN 2 YLMETHOXY]PHENOXYPHOSPHORYLAMINO]PROPIONIC ACID ISOPROPYL ESTER; 4' AZIDOCYTIDINE; BENZOTHIADIAZINE DERIVATIVE; CARBOXYLESTERASE; CARBOXYPEPTIDASE C; GEMCITABINE; INDOLE DERIVATIVE; INX 08189; NESBUVIR; PHOSPHORAMIDIC ACID DERIVATIVE; PROTEIN; PROTEIN ADAL1; PROTEIN HINT 1; PSI 352666; PSI 352878; PSI 353131; PSI 353222; PSI 353224; PSI 353579; PSI 353661; PSI 6567; PSI 7851; TELAPREVIR; THIOPHENE DERIVATIVE; UNCLASSIFIED DRUG; ZALCITABINE;

ANTIVIRAL ACTIVITY; ARTICLE; DRUG METABOLISM; DRUG POTENCY; DRUG SELECTIVITY; HEMATOPOIETIC STEM CELL; HEPATITIS C VIRUS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; VIRUS INHIBITION; VIRUS REPLICATION;

5'-GUANYLIC ACID; ANTIVIRAL AGENTS; BIOTRANSFORMATION; CATHEPSIN A; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CLONING, MOLECULAR; DRUG EVALUATION, PRECLINICAL; GUANYLATE KINASE; HEP G2 CELLS; HEPACIVIRUS; HEPATOCYTES; HUMANS; LACTIC ACID; LUCIFERASES; MICROBIAL SENSITIVITY TESTS; MITOCHONDRIA; MUTATION; NERVE TISSUE PROTEINS; PHENOL; PHOSPHORYLATION; PRODRUGS; REPLICON; VIRAL NONSTRUCTURAL PROTEINS; VIRUS REPLICATION;

HEPATITIS C VIRUS;

EID: 79958255214     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2011.05.003     Document Type: Article

References (36)

1. Afdahl, N., Godofsky, E., Dienstag, J., Rustgi, V.K., Schick, L., McEniry, D., Zhou, X.-J., Chao, G., Fang, C., Fielman, B., Myers, M., Brown, N., 2004. Final phase I/II trial results for NM283, a new polymerase inhibitor for hepatitis C: antiviral efficacy and tolerance in patients with HCV-1 infection, including previous interferon failures, 55th Annual Meeting of the American Association for the Study of Liver Diseases, Boston, MA, USA, p. 726A.
2. Blight K.J., McKeating J.A., Marcotrigiano J., Rice C.M. Efficient replication of hepatitis C virus genotype 1a RNAs in cell culture. J. Virol. 2003, 77:3181-3190.
3. Chang W., Bao D., Chun B.K., Naduthambi D., Nagaratham D., Rachakonda S., Reddy P.G., Ross B.S., Zhang H.R., Bansal S., Espiritu C., Keilman M., Lam A.M., Niu C., Micholochick Steuer H.M., Furman P.A., Otto M.J., Sofia M.J. Discovery of PSI-353661, a novel purine nucleotide prodrug for the treatment of HCV infection. ACS Med. Chem. Lett. 2010, 2:130-135.
4. Chou T.F., Baraniak J., Kaczmarek R., Zhou X., Cheng J., Ghosh B., Wagner C.R. Phosphoramidate pronucleotides: a comparison of the phosphoramidase substrate specificity of human and Escherichia coli histidine triad nucleotide binding proteins. Mol. Pharm. 2007, 4:208-217.
5. Clark J.L., Mason J.C., Hollecker L., Stuyver L.J., Tharnish P.M., McBrayer T.R., Otto M.J., Furman P.A., Schinazi R.F., Watanabe K.A. Synthesis and antiviral activity of 2′-deoxy-2′-fluoro-2′-C-methyl purine nucleosides as inhibitors of hepatitis C virus RNA replication. Bioorg. Med. Chem. Lett. 2006, 16:1712-1715.
6. Duarte M.I., Andrade H.F., Mariano O.N., Corbett C.E., Sesso A. Baseline volume data of human liver parenchymal cell. J. Submicrosc. Cytol. Pathol. 1989, 21:275-279.
7. Fleischer R.D., Lok A.S. Myopathy and neuropathy associated with nucleos(t)ide analog therapy for hepatitis B. J. Hepatol. 2009, 51:787-791.
8. Herlihy K.J., Graham J.P., Kumpf R., Patick A.K., Duggal R., Shi S.T. Development of intergenotypic chimeric replicons to determine the broad-spectrum antiviral activities of hepatitis C virus polymerase inhibitors. Antimicrob. Agents Chemother. 2008, 52:3523-3531.
9. Howe A.Y., Cheng H., Johann S., Mullen S., Chunduru S.K., Young D.C., Bard J., Chopra R., Krishnamurthy G., Mansour T., O'Connell J. Molecular mechanism of hepatitis C virus replicon variants with reduced susceptibility to a benzofuran inhibitor, HCV-796. Antimicrob. Agents Chemother. 2008, 52:3327-3338.
10. Koutsoudakis G., Herrmann E., Kallis S., Bartenschlager R., Pietschmann T. The level of CD81 cell surface expression is a key determinant for productive entry of hepatitis C virus into host cells. J. Virol. 2007, 81:588-598.
11. Krishnan P., Fu Q., Lam W., Liou J.Y., Dutschman G., Cheng Y.C. Phosphorylation of pyrimidine deoxynucleoside analog diphosphates: selective phosphorylation of l-nucleoside analog diphosphates by 3-phosphoglycerate kinase. J. Biol. Chem. 2002, 277:5453-5459.
12. Lam A.M., Murakami E., Espiritu C., Steuer H.M., Niu C., Keilman M., Bao H., Zennou V., Bourne N., Julander J.G., Morrey J.D., Smee D.F., Frick D.N., Heck J.A., Wang P., Nagarathnam D., Ross B.S., Sofia M.J., Otto M.J., Furman P.A. PSI-7851, a pronucleotide of beta-D-2′-deoxy-2′-fluoro-2′-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication. Antimicrob. Agents Chemother. 2010, 54:3187-3196.
13. Le Pogam S., Jiang W.R., Leveque V., Rajyaguru S., Ma H., Kang H., Jiang S., Singer M., Ali S., Klumpp K., Smith D., Symons J., Cammack N., Najera I. In vitro selected Con1 subgenomic replicons resistant to 2′-C-methyl-cytidine or to R1479 show lack of cross resistance. Virology 2006, 351:349-359.
14. Le Pogam S., Kang H., Harris S.F., Leveque V., Giannetti A.M., Ali S., Jiang W.R., Rajyaguru S., Tavares G., Oshiro C., Hendricks T., Klumpp K., Symons J., Browner M.F., Cammack N., Najera I. Selection and characterization of replicon variants dually resistant to thumb- and palm-binding nonnucleoside polymerase inhibitors of the hepatitis C virus. J. Virol. 2006, 80:6146-6154.
15. Lewis W., Day B.J., Copeland W.C. Mitochondrial toxicity of NRTI antiviral drugs: an integrated cellular perspective. Nat. Rev. Drug Discov. 2003, 2:812-822.
16. Lohmann V., Hoffmann S., Herian U., Penin F., Bartenschlager R. Viral and cellular determinants of hepatitis C virus RNA replication in cell culture. J. Virol. 2003, 77:3007-3019.
17. McCown M.F., Rajyaguru S., Le Pogam S., Ali S., Jiang W.R., Kang H., Symons J., Cammack N., Najera I. The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors. Antimicrob. Agents Chemother. 2008, 52:1604-1612.
18. McGuigan C., Sutton P.W., Cahard D., Turner K., O'Leary G., Wang Y., Gumbleton M., De Clercq E., Balzarini J. Synthesis, anti-human immunodeficiency virus activity and esterase lability of some novel carboxylic ester-modified phosphoramidate derivatives of stavudine (d4T). Antivir. Chem. Chemother. 1998, 9:473-479.
19. McGuigan C., Tsang H.W., Sutton P.W., De Clercq E., Balzarini J. Synthesis and anti-HIV activity of some novel chain-extended phosphoramidate derivatives of d4T (stavudine): esterase hydrolysis as a rapid predictive test for antiviral potency. Antivir. Chem. Chemother. 1998, 9:109-115.
20. McGuigan C., Madela K., Aljarah M., Gilles A., Brancale A., Zonta N., Chamberlain S., Vernachio J., Hutchins J., Hall A., Ames B., Gorovits E., Ganguly B., Kolykhalov A., Wang J., Muhammad J., Patti J.M., Henson G. Design, synthesis and evaluation of a novel double pro-drug: INX-08189. A new clinical candidate for hepatitis C virus. Bioorg. Med. Chem. Lett. 2010, 20:4850-4854.
21. Migliaccio G., Tomassini J.E., Carroll S.S., Tomei L., Altamura S., Bhat B., Bartholomew L., Bosserman M.R., Ceccacci A., Colwell L.F., Cortese R., De Francesco R., Eldrup A.B., Getty K.L., Hou X.S., LaFemina R.L., Ludmerer S.W., MacCoss M., McMasters D.R., Stahlhut M.W., Olsen D.B., Hazuda D.J., Flores O.A. Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro. J. Biol. Chem. 2003, 278:49164-49170.
22. Moyle G. Toxicity of antiretroviral nucleoside and nucleotide analogues: is mitochondrial toxicity the only mechanism?. Drug Saf. 2000, 23:467-481.
23. Murakami E., Bao H., Ramesh M., McBrayer T.R., Whitaker T., Micolochick Steuer H.M., Schinazi R.F., Stuyver L.J., Obikhod A., Otto M.J., Furman P.A. Mechanism of activation of beta-D-2′-deoxy-2′-fluoro-2′-c-methylcytidine and inhibition of hepatitis C virus NS5B RNA polymerase. Antimicrob. Agents Chemother. 2007, 51:503-509.
24. Murakami E., Niu C., Bao H., Micolochick Steuer H.M., Whitaker T., Nachman T., Sofia M.A., Wang P., Otto M.J., Furman P.A. The mechanism of action of beta-D-2′-deoxy-2′-fluoro-2′-C-methylcytidine involves a second metabolic pathway leading to beta-D-2′-deoxy-2′-fluoro-2′-C-methyluridine 5′-triphosphate, a potent inhibitor of the hepatitis C virus RNA-dependent RNA polymerase. Antimicrob. Agents Chemother. 2008, 52:458-464.
25. Murakami E., Tolstykh T., Bao H., Niu C., Micolochick Steuer H.M., Bao D., Chang W., Espiritu C., Bansal S., Lam A.M., Otto M.J., Sofia M.J., Furman P.A. Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977. J. Biol. Chem. 2010, 285:34337-34347.
26. Nelson, D., Pockors, P., Godofsky, E., Rodriguez-Torres, M., Everson, G., Fried, M., R., G., Harrison, S., Nyberg, L., Shiffman, M., Chan, A., Hill, G., 2008. High end-of-treatment response (84%) after 4weeks of R1626, peginterferon alfa-2A (40kDa) and ribavirin followed by a further 44weeks of peginterferon alfa-2A and ribavirin., 43rd Annual Meeting of the European Association for the Study of the Liver (EASL), Milan, Italy.
27. Nguyen T.T., Gates A.T., Gutshall L.L., Johnston V.K., Gu B., Duffy K.J., Sarisky R.T. Resistance profile of a hepatitis C virus RNA-dependent RNA polymerase benzothiadiazine inhibitor. Antimicrob. Agents Chemother. 2003, 47:3525-3530.
28. 6-substituted purine acyclic nucleoside phosphonates. Biochem. Pharmacol. 2006, 71:1370-1376.
29. 6-substituted purine acyclic nucleoside phosphonates. Collect. Czech. Chem. Commun. 2008, 73:275-291.
30. Sofia M.J., Bao D., Chang W., Du J., Nagarathnam D., Rachakonda S., Reddy P.G., Ross B.S., Wang P., Zhang H.R., Bansal S., Espiritu C., Keilman M., Lam A.M., Steuer H.M., Niu C., Otto M.J., Furman P.A. Discovery of a beta-d-2′-deoxy-2′-alpha-fluoro-2′-beta-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus. J. Med. Chem. 2010, 53:7202-7218.
31. Stuyver L.J., Lostia S., Adams M., Mathew J.S., Pai B.S., Grier J., Tharnish P.M., Choi Y., Chong Y., Choo H., Chu C.K., Otto M.J., Schinazi R.F. Antiviral activities and cellular toxicities of modified 2′,3′-dideoxy-2′,3′-didehydrocytidine analogues. Antimicrob. Agents Chemother. 2002, 46:3854-3860.
32. Stuyver L.J., McBrayer T.R., Tharnish P.M., Hassan A.E., Chu C.K., Pankiewicz K.W., Watanabe K.A., Schinazi R.F., Otto M.J. Dynamics of subgenomic hepatitis C virus replicon RNA levels in Huh-7 cells after exposure to nucleoside antimetabolites. J. Virol. 2003, 77:10689-10694.
33. Stuyver L.J., McBrayer T.R., Tharnish P.M., Clark J., Hollecker L., Lostia S., Nachman T., Grier J., Bennett M.A., Xie M.Y., Schinazi R.F., Morrey J.D., Julander J.L., Furman P.A., Otto M.J. Inhibition of hepatitis C replicon RNA synthesis by beta-D-2′-deoxy-2′-fluoro-2′-C-methylcytidine: a specific inhibitor of hepatitis C virus replication. Antivir. Chem Chemother. 2006, 17:79-87.
34. Tanji N., Tanji K., Kambham N., Markowitz G.S., Bell A., D'Agati V.D. Adefovir nephrotoxicity: possible role of mitochondrial DNA depletion. Hum. Pathol. 2001, 32:734-740.
35. Tomei L., Altamura S., Bartholomew L., Biroccio A., Ceccacci A., Pacini L., Narjes F., Gennari N., Bisbocci M., Incitti I., Orsatti L., Harper S., Stansfield I., Rowley M., De Francesco R., Migliaccio G. Mechanism of action and antiviral activity of benzimidazole-based allosteric inhibitors of the hepatitis C virus RNA-dependent RNA polymerase. J. Virol. 2003, 77:13225-13231.
36. Yi M., Villanueva R.A., Thomas D.L., Wakita T., Lemon S.M. Production of infectious genotype 1a hepatitis C virus (Hutchinson strain) in cultured human hepatoma cells. Proc. Natl. Acad. Sci. USA 2006, 103:2310-2315.